Sleep disordered breathing and metabolic comorbidities across sex and menopausal status in East Asians: the Nagahama Study.
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
21
11
2019
accepted:
20
04
2020
pubmed:
16
5
2020
medline:
22
6
2021
entrez:
16
5
2020
Statut:
epublish
Résumé
It is well known that the prevalence of sleep disordered breathing (SDB) is increased in patients with obesity or metabolic comorbidities. However, the way in which the prevalence of SDB increases in relation to comorbidities according to the severity of obesity remains unclear.This cross-sectional study evaluated 7713 community participants using nocturnal oximetry ≥2 nights. SDB was assessed by the 3% oxygen desaturation index corrected for sleep duration obtained by wrist actigraphy (acti-ODI3%). SDB severity was defined by acti-ODI3%. Obesity was defined as body mass index ≥25 kg·m
Identifiants
pubmed: 32409572
pii: 13993003.02251-2019
doi: 10.1183/13993003.02251-2019
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright ©ERS 2020.
Déclaration de conflit d'intérêts
Conflict of interest: T. Matsumoto has nothing to disclose. K. Murase reports grants from Philips-Respironics, Teijin Pharma, Fukuda Denshi, Fukuda Lifetec Keiji, ResMed and Japan Society for the Promotion of Science, outside the submitted work. Conflict of interest: Y. Tabara reports grants from Japan Agency for Medical Research and Development (AMED) and The Ministry of Education, Culture, Sports, Science and Technology in Japan, during the conduct of the study. Conflict of interest: T. Minami reports personal fees from Teijin Zaitakuiryou, outside the submitted work. Conflict of interest: O. Kanai has nothing to disclose. Conflict of interest: H. Takeyama reports grants from Philips-Respironics, ResMed, Fukuda Denshi, Fukuda Lifetec Keiji and Teijin Pharma, outside the submitted work. Conflict of interest: N. Takahashi reports grants from Philips-Respironics, ResMed, Fukuda Denshi and Fukuda Lifetec Keiji, outside the submitted work. Conflict of interest: S. Hamada reports grants from Teijin Pharma, outside the submitted work. Conflict of interest: K. Tanizawa has nothing to disclose. Conflict of interest: T. Wakamura has nothing to disclose. Conflict of interest: N. Komenami has nothing to disclose. Conflict of interest: K. Setoh has nothing to disclose. Conflict of interest: T. Kawaguchi has nothing to disclose. Conflict of interest: T. Tsutsumi has nothing to disclose. Conflict of interest: S. Morita has nothing to disclose. Conflict of interest: Y. Takahashi has nothing to disclose. Conflict of interest: T. Nakayama has nothing to disclose. Conflict of interest: T. Hirai has nothing to disclose. Conflict of interest: F. Matsuda reports grants from Kyoto University, the Ministry of Education, Culture, Sports, Science and Technology in Japan, Japan Agency for Medical Research and Development (AMED) and The Takeda Medical Research Foundation, during the conduct of the study. Conflict of interest: K. Chin reports grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology, grants from the Intractable Respiratory Diseases and Pulmonary Hypertension Research Group, the Ministry of Health, Labour and Welfare, Japan, grants from the Research Foundation for Healthy Aging, grants from Health, Labour and Welfare Sciences Research Grants, Research on Region Medical, grants from the Center of Innovation Program, and the Global University Project from Japan Science and Technology Agency, Japan Agency for Medical Research and Development, during the conduct of the study; grants and personal fees from Philips-Respironics, Teijin Pharma, Fukuda Denshi, Fukuda Lifetec Keiji, GlaxoSmithKline and Resmed, grants from KYORIN Pharmaceutical Co., Ltd and Nippon Boehringer Ingelheim Co., Ltd, personal fees from MSD, Astellas Pharma and Eisai Co., Ltd, outside the submitted work.